Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Marimed (MRMD) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Marimed (MRMD) over the last 13 years, with Q3 2025 value amounting to $8.0 million.

  • Marimed's Other Operating Expenses fell 1047.29% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.4 million, marking a year-over-year decrease of 239.21%. This contributed to the annual value of $33.4 million for FY2024, which is 1630.26% up from last year.
  • As of Q3 2025, Marimed's Other Operating Expenses stood at $8.0 million, which was down 1047.29% from $8.4 million recorded in Q2 2025.
  • Over the past 5 years, Marimed's Other Operating Expenses peaked at $9.6 million during Q1 2025, and registered a low of $2.1 million during Q3 2021.
  • Its 5-year average for Other Operating Expenses is $6.4 million, with a median of $7.4 million in 2024.
  • Data for Marimed's Other Operating Expenses shows a peak YoY increase of 20593.21% (in 2021) and a maximum YoY decrease of 1148.94% (in 2021) over the last 5 years.
  • Marimed's Other Operating Expenses (Quarter) stood at $3.7 million in 2021, then surged by 140.82% to $8.8 million in 2022, then fell by 6.44% to $8.2 million in 2023, then fell by 10.79% to $7.4 million in 2024, then increased by 9.12% to $8.0 million in 2025.
  • Its Other Operating Expenses stands at $8.0 million for Q3 2025, versus $8.4 million for Q2 2025 and $9.6 million for Q1 2025.